GEHC
Bullish signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
GE HealthCare Technologies Inc.
- Nom
- GE HealthCare Technologies Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $32.4B
- Employés
- 54,000
- PDG
- Peter J. Arduini
- Site web
- https://www.gehealthcare.com
- Marché
- ABTBSXFUJIYMDTOCPNFPHG
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-11 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-07-30 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-07-07 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-07-06 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-07-02 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-07-07 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-07-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-07-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-06-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-03-25 | Terri Sewell | Sale (Full) | $1,001 - $15,000 |
| 2026-03-23 | Warren Davidson | Sale (Full) | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-03-27 | Austin Scott | Sale (Full) | $1,001 - $15,000 |
| 2025-02-25 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-20 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2023-01-20 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2023-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-01-04 | Austin Scott | Exchange | $1,001 - $15,000 |
Signal
Bullish signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
GEHC presents a compelling event-driven opportunity anchored by the confirmed $945M Sofie Biosciences acquisition, strategically expanding its fastest-growing radiopharmaceuticals segment with high catalyst confidence…
The first sentence of the analysis written for GEHC on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Supports a bullish reading. 6 purchase disclosures year to date
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.18 · operating margin 13%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 40.0% | 41.7% | 40.5% | 39.1% | 40.8% | |
| Ebit Margin | 15.5% | 15.7% | 14.8% | 13.8% | 16.6% | |
| Ebitda Margin | 18.4% | 18.6% | 18.0% | 17.3% | 20.1% | |
| Operating Profit Margin | 13.4% | 13.3% | 12.5% | 13.8% | 15.9% | |
| Pretax Profit Margin | 13.4% | 13.1% | 12.1% | 13.7% | 16.3% | |
| Continuous Operations Profit Margin | 10.4% | 10.4% | 8.3% | 10.6% | 12.9% | |
| Net Profit Margin | 10.1% | 10.1% | 8.0% | 10.4% | 12.8% | |
| Bottom Line Profit Margin | 10.1% | 10.1% | 7.1% | 10.3% | 12.8% | |
| Current Ratio | 1.175 | 0.996 | 1.003 | 1.087 | 0.968 | |
| Quick Ratio | 0.930 | 0.793 | 0.785 | 0.788 | 0.680 | |
| Solvency Ratio | 0.101 | 0.105 | 0.087 | 0.142 | 0.305 | |
| Cash Ratio | 0.496 | 0.303 | 0.279 | 0.201 | 0.082 | |
| Price To Earnings Ratio | 17.987 | 17.890 | 25.434 | 13.834 | 12.245 | |
| Price To Earnings Growth Ratio | 4.137 | 0.409 | -0.910 | -0.997 | 1.102 | |
| Forward Price To Earnings Growth Ratio | 4.137 | 0.409 | -0.910 | -0.997 | 1.102 | |
| Price To Earnings Diluted Ratio | 18.026 | 18.014 | 25.603 | 13.834 | 12.245 | |
| Price To Earnings Diluted Growth Ratio | 3.725 | 0.412 | -0.900 | -0.997 | 1.102 | |
| Price To Book Ratio | 3.608 | 4.220 | 4.932 | 2.832 | 1.638 | |
| Price To Sales Ratio | 1.815 | 1.812 | 1.799 | 1.445 | 1.551 | |
| Price To Free Cash Flow Ratio | 24.863 | 23.000 | 20.525 | 14.698 | 20.075 | |
| Price To Operating Cash Flow Ratio | 18.835 | 18.273 | 16.745 | 12.542 | 16.977 | |
| Debt To Assets Ratio | 0.271 | 0.283 | 0.304 | 0.314 | 0.017 | |
| Debt To Equity Ratio | 0.964 | 1.110 | 1.383 | 0.923 | 0.026 | |
| Debt To Capital Ratio | 0.491 | 0.526 | 0.580 | 0.480 | 0.026 | |
| Long Term Debt To Capital Ratio | 0.478 | 0.469 | 0.542 | 0.468 | 0.002 | |
| Financial Leverage Ratio | 3.556 | 3.917 | 4.550 | 2.943 | 1.580 | |
| Working Capital Turnover Ratio | 26.459 | -4,918.000 | 59.519 | 89.468 | -27.179 | |
| Operating Cash Flow Ratio | 0.218 | 0.204 | 0.234 | 0.294 | 0.238 | |
| Operating Cash Flow Sales Ratio | 0.096 | 0.099 | 0.107 | 0.115 | 0.091 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.758 | 0.794 | 0.816 | 0.853 | 0.846 | |
| Debt Service Coverage Ratio | 3.310 | 1.562 | 1.671 | 12.693 | 19.600 | |
| Interest Coverage Ratio | 6.138 | 5.198 | 4.493 | 29.326 | 69.875 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.913 | 1.299 | 1.883 | 17.756 | 14.609 | |
| Operating Cash Flow Coverage Ratio | 0.199 | 0.208 | 0.213 | 0.245 | 3.677 | |
| Capital Expenditure Coverage Ratio | 4.124 | 4.865 | 5.429 | 6.816 | 6.480 | |
| Dividend Paid And Capex Coverage Ratio | 3.641 | 4.279 | 4.909 | 6.816 | 6.480 | |
| Dividend Payout Ratio | 0.031 | 0.028 | 0.026 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 11.343 | 11.494 | 12.109 | 10.645 | 7.673 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 40.0% | ▼-1.7% | ▼-0.4% |
| Ebit Margin | 15.6% | ▼-0.1% | ▲0.3% |
| Ebitda Margin | 18.4% | ▼-0.3% | ▼-0.1% |
| Operating Profit Margin | 13.4% | ▲0.1% | ▼-0.4% |
| Pretax Profit Margin | 13.4% | ▲0.3% | ▼-0.3% |
| Continuous Operations Profit Margin | 10.4% | ▲0.0% | ▼-0.1% |
| Net Profit Margin | 10.1% | ▼-0.0% | ▼-0.2% |
| Bottom Line Profit Margin | 10.1% | ▼-0.0% | ▲0.0% |
| Current Ratio | 1.175 | ▲0.179 | ▲0.129 |
| Quick Ratio | 0.930 | ▲0.137 | ▲0.135 |
| Solvency Ratio | 0.101 | ▼-0.004 | ▼-0.047 |
| Cash Ratio | 0.496 | ▲0.193 | ▲0.224 |
| Price To Earnings Ratio | 17.987 | ▲0.097 | ▲0.509 |
| Price To Earnings Growth Ratio | 4.137 | ▲3.728 | ▲3.389 |
| Forward Price To Earnings Growth Ratio | 4.137 | ▲3.728 | ▲3.389 |
| Price To Earnings Diluted Ratio | 18.026 | ▲0.013 | ▲0.482 |
| Price To Earnings Diluted Growth Ratio | 3.725 | ▲3.313 | ▲3.057 |
| Price To Book Ratio | 3.608 | ▼-0.613 | ▲0.162 |
| Price To Sales Ratio | 1.815 | ▲0.003 | ▲0.131 |
| Price To Free Cash Flow Ratio | 24.863 | ▲1.863 | ▲4.231 |
| Price To Operating Cash Flow Ratio | 18.835 | ▲0.562 | ▲2.161 |
| Debt To Assets Ratio | 0.271 | ▼-0.012 | ▲0.033 |
| Debt To Equity Ratio | 0.964 | ▼-0.146 | ▲0.083 |
| Debt To Capital Ratio | 0.491 | ▼-0.035 | ▲0.070 |
| Long Term Debt To Capital Ratio | 0.478 | ▲0.009 | ▲0.086 |
| Financial Leverage Ratio | 3.556 | ▼-0.361 | ▲0.247 |
| Working Capital Turnover Ratio | 26.459 | ▲4944.459 | ▲980.406 |
| Operating Cash Flow Ratio | 0.218 | ▲0.014 | ▼-0.019 |
| Operating Cash Flow Sales Ratio | 0.096 | ▼-0.003 | ▼-0.005 |
| Free Cash Flow Operating Cash Flow Ratio | 0.757 | ▼-0.037 | ▼-0.056 |
| Debt Service Coverage Ratio | 3.310 | ▲1.748 | ▼-4.457 |
| Interest Coverage Ratio | 6.138 | ▲0.940 | ▼-16.868 |
| Short Term Operating Cash Flow Coverage Ratio | 3.913 | ▲2.615 | ▼-3.979 |
| Operating Cash Flow Coverage Ratio | 0.199 | ▼-0.009 | ▼-0.710 |
| Capital Expenditure Coverage Ratio | 4.125 | ▼-0.741 | ▼-1.419 |
| Dividend Paid And Capex Coverage Ratio | 3.641 | ▼-0.637 | ▼-1.584 |
| Dividend Payout Ratio | 0.031 | ▲0.003 | ▲0.014 |
| Enterprise Value Multiple | 11.343 | ▼-0.150 | ▲0.691 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $37.44B | $35.65B | $35.18B | $26.50B | $27.28B | |
| Enterprise value | $42.93B | $42.14B | $42.54B | $33.69B | $27.16B | |
| EV / Sales | 2.08x | 2.14x | 2.18x | 1.84x | 1.54x | |
| EV / Op. cash flow | 21.60x | 21.60x | 20.25x | 15.94x | 16.90x | |
| EV / Free cash flow | 28.51x | 27.18x | 24.82x | 18.69x | 19.99x | |
| EV / EBITDA | 11.34x | 11.49x | 12.11x | 10.64x | 7.67x | |
| Net debt / EBITDA | 1.45x | 1.77x | 2.10x | 2.27x | -0.03x | |
| Current ratio | 1.18x | 1.00x | 1.00x | 1.09x | 0.97x | |
| Income quality | 0.92x | 0.95x | 1.30x | 1.08x | 0.71x | |
| Graham number | $48 | $43 | $35 | $44 | $64 | |
| Graham net-net | -$39 | -$38 | -$40 | -$27 | -$11 | |
| Tax burden | 75.3% | 77.2% | 66.4% | 76.3% | 78.2% | |
| Interest burden | 86.3% | 83.6% | 81.3% | 99.2% | 98.6% | |
| Working capital | $1.60B | -$37.0M | $29.0M | $628.0M | -$218.0M | |
| Invested capital | $19.31B | $16.73B | $16.72B | $17.27B | $16.76B | |
| Return on assets | 5.6% | 6.0% | 4.8% | 7.0% | 8.5% | |
| Operating ROA | 7.9% | 8.0% | 8.1% | 9.4% | 11.1% | |
| Return on tangible assets | 9.4% | 10.6% | 8.6% | 14.5% | 19.4% | |
| Return on equity | 20.1% | 23.6% | 22.0% | 20.5% | 13.5% | |
| Return on invested capital | 8.8% | 8.3% | 6.8% | 9.6% | 11.3% | |
| Return on capital employed | 9.9% | 11.2% | 10.4% | 12.4% | 14.3% | |
| Earnings yield | 5.6% | 5.6% | 4.5% | 7.2% | 8.2% | |
| Free cash flow yield | 4.0% | 4.3% | 4.9% | 6.8% | 5.0% | |
| Capex / Op. cash flow | 24.2% | 20.6% | 18.4% | 14.7% | 15.4% | |
| Capex / Depreciation | 83.4% | 69.1% | 63.4% | 49.0% | 39.7% | |
| Capex / Sales | 2.3% | 2.0% | 2.0% | 1.7% | 1.4% | |
| SG&A / Sales | 20.5% | 21.7% | 21.9% | 19.8% | 20.3% | |
| R&D / Sales | 6.1% | 6.7% | 6.2% | 5.6% | 4.6% | |
| Stock comp / Sales | 0.6% | 0.6% | 0.6% | 0.4% | 0.4% | |
| Intangibles / Total assets | 39.6% | 43.0% | 43.7% | 52.0% | 56.0% | |
| Days sales outstanding | 70d | 81d | 81d | 79d | 79d | |
| Days payables outstanding | 96d | 96d | 92d | 101d | 96d | |
| Operating cycle | 136d | 143d | 142d | 150d | 147d | |
| Cash conversion cycle | 40d | 47d | 50d | 49d | 51d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company''s possible violations of the federal securities laws.
- 2026-10-05 GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
- 2026-10-05 GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition GE Healthcare Technologies will purchase radiopharmaceutical company Sofie Biosciences to expand into a lucrative therapeutic area.
- 2026-10-05 GE HealthCare to Acquire SOFIE Biosciences, Establishing a ''Final Mile'' Footprint for PET Radiopharmaceutical Supply in the U.S. CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare''s PDx segment. The acquisition of SOFIE Biosci.
- 2026-10-05 GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical imaging procedures like PET scans The deal expands GE HealthCare''s footprint in radiopharmaceuticals, its fastest-growing segment.
- 2026-10-02 Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company''s possible violations of federal securities laws.
- 2026-10-02 GEHC vs. SYK: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
- 2026-09-30 GE HealthCare (GEHC) Upgraded to Buy: Here''s Why GE HealthCare (GEHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-09-28 Here''s Why You Should Add GEHC Stock to Your Portfolio Right Now GEHC''s record backlog, strong orders and AI-enabled innovations offer growth potential, while inflation and China remain key risks.
- 2026-09-22 GE HealthCare announces cash dividend increase for third quarter of 2026 CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.04 per share of Common Stock for the third quarter of 2026, an increase of 14% from the previous quarter. The dividend will be payable on November 13, 2026, to all shareholders of record as of October 23, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical dia.